CA, Rhodes GA, Robey RL, et al. (1997) Design, synthesis, and pharmacological
characterization of ( )-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
(LY354740): a potent, selective, and orally active group 2 metabotropic glutamate
receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem
40:528 –537.
Ohishi H, Shigemoto R, Nakanishi S, and Mizuno N (1993a) Distribution of the
messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central
nervous system of the rat. Neuroscience 53:1009 –1018.
Ohishi H, Shigemoto R, Nakanishi S, and Mizuno N (1993b) Distribution of the
mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ
hybridization study. J Comp Neurol 335:252–266.
Pin JP and Duvoisin R (1995) The metabotropic glutamate receptors: structure and
functions. Neuropharmacology 34:1–26.
Rasmussen K, Calligaro DO, Czachura JF, Dreshfield-Ahmad LJ, Evans DC, Hemrick-Luecke SK, Kallman MJ, Kendrick WT, Leander JD, Nelson DL, et al. (2000)
The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine
withdrawal and interactions with fluoxetine. J Pharmacol Exp Ther 294:688 –700.
Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD,
and McKinzie DL (2006) Improved bioavailability of the mGlu2/3 receptor agonist
LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 316:905–913.
Sachdev PS (2005) Neuroleptic-induced movement disorders: an overview. Psychiatr
Clin North Am 28:255–274.
Schoepp DD, Jane DE, and Monn JA (1999a) Pharmacological agents acting at
subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431–1476.
Schoepp DD, Johnson BG, Salhoff CR, Valli MJ, Desai MA, Burnett JP, Mayne NG,
and Monn JA (1995) Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine- 2,4-dicarboxylate. Neuropharmacology 34:843– 850.
Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerman SL,
Burnett JP, Belegaje R, Bleakman D, et al. (1997) LY354740 is a potent and highly
selective group II metabotropic glutamate receptor agonist in cells expressing
human glutamate receptors. Neuropharmacology 36:1–11.
